Replimune Group, Inc. — Director's Dealing 2018

Jul 20, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2018-07-19

Reporting Person: Rhodes Jason P (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (3439839)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (1013547)		Indirect

Footnotes

F1: At any time at the holder's election or automatically upon the consummation of the Issuer's initial public offering, each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock is convertible into shares of the Issuer's common stock on a 1-for-9.94688 basis without payment of consideration. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock have no expiration date.

F2: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.